Compare AJANTA PHARMA with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA STERLING BIOTECH AJANTA PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 24.5 -0.4 - View Chart
P/BV x 6.8 0.0 47,856.6% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 AJANTA PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
STERLING BIOTECH
Dec-13
AJANTA PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,42211 13,541.9%   
Low Rs8983 26,400.0%   
Sales per share (Unadj.) Rs233.526.8 871.1%  
Earnings per share (Unadj.) Rs44.0-15.0 -293.9%  
Cash flow per share (Unadj.) Rs52.2-5.5 -954.7%  
Dividends per share (Unadj.) Rs9.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs255.154.9 464.8%  
Shares outstanding (eoy) m88.02267.87 32.9%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.00.3 1,915.6%   
Avg P/E ratio x26.4-0.5 -5,677.1%  
P/CF ratio (eoy) x22.2-1.3 -1,747.9%  
Price / Book Value ratio x4.50.1 3,590.3%  
Dividend payout %20.50-   
Avg Mkt Cap Rs m102,0811,862 5,483.2%   
No. of employees `0006.81.4 502.2%   
Total wages/salary Rs m4,307547 787.7%   
Avg. sales/employee Rs Th3,022.65,303.3 57.0%   
Avg. wages/employee Rs Th633.4403.8 156.8%   
Avg. net profit/employee Rs Th569.1-2,959.0 -19.2%   
INCOME DATA
Net Sales Rs m20,5547,181 286.2%  
Other income Rs m21143 494.8%   
Total revenues Rs m20,7657,223 287.5%   
Gross profit Rs m5,664947 598.2%  
Depreciation Rs m7212,543 28.3%   
Interest Rs m124,377 0.3%   
Profit before tax Rs m5,143-5,931 -86.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,273-1,924 -66.2%   
Profit after tax Rs m3,870-4,007 -96.6%  
Gross profit margin %27.613.2 209.0%  
Effective tax rate %24.832.4 76.3%   
Net profit margin %18.8-55.8 -33.7%  
BALANCE SHEET DATA
Current assets Rs m11,81214,335 82.4%   
Current liabilities Rs m3,77649,809 7.6%   
Net working cap to sales %39.1-494.0 -7.9%  
Current ratio x3.10.3 1,086.9%  
Inventory Days Days77403 19.2%  
Debtors Days Days82171 47.8%  
Net fixed assets Rs m14,39855,432 26.0%   
Share capital Rs m175268 65.5%   
"Free" reserves Rs m22,27713,935 159.9%   
Net worth Rs m22,45214,701 152.7%   
Long term debt Rs m79,478 0.1%   
Total assets Rs m26,96273,988 36.4%  
Interest coverage x444.3-0.4 -125,178.9%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.80.1 785.5%   
Return on assets %14.40.5 2,874.0%  
Return on equity %17.2-27.3 -63.2%  
Return on capital %23.0-6.4 -357.2%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m10,6821,860 574.3%   
Fx outflow Rs m2,10225 8,444.8%   
Net fx Rs m8,5801,835 467.6%   
CASH FLOW
From Operations Rs m3,7481,719 218.1%  
From Investments Rs m-2,228-3,148 70.8%  
From Financial Activity Rs m-1,4751,426 -103.4%  
Net Cashflow Rs m45-3 -1,329.4%  

Share Holding

Indian Promoters % 73.8 33.9 217.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.0 -  
FIIs % 7.6 9.9 76.8%  
ADR/GDR % 0.0 16.9 -  
Free float % 17.0 39.3 43.3%  
Shareholders   20,968 21,482 97.6%  
Pledged promoter(s) holding % 4.4 55.9 7.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ALEMBIC  SUN PHARMA  PIRAMAL ENTERPRISES  FDC  NEULAND LABS  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 598 Points Lower, Nifty Settles Below 15,100-Mark; HDFC and JSW Steel Top Losers(Closing)

Indian share markets witnessed huge selling during closing hours today and ended their day deep in the red.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Mar 4, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS